A scrutinized reflection on multiple sclerosis in Middle East countries

Abstract

Introduction MS or Multiple Sclerosis is a chronic - progressive disease involving nerve cells sheath of the brain and spinal cord [1]. Recent studies observe the connotation between socioeconomic status (SES) and disability outcomes and progression in MS. The association between SES at MS onset sustained and confirmed Expanded Disability Status Scale (EDSS) 6.0 and 4.0 and onset of secondary progression of MS [2]. Demographic details According to WHO, MS is rapidly increased in the Middle East and North African countries. In 2015, it was observed that the prevalence is 115.94 per 10 thousand population and the women were most affected. A mean age of MS onset is identified as 28.54 yrs. The most common pretentious type of MS in the Middle East were relapsing remitting multiple sclerosis (RRMS) (87.8% in Iran)[3]. Recent advancement According to the recent (2018) evidence, FDA accepted to re-evaluate the Cladribine – an immunosuppressant drug for treatment of RRMS [4]. Oral fingolimod is identified as advanced disease modifying therapy against MS, even for pediatric patients [6]. A current (2019) prospective study sought to investigate autologous hematopoietic stem cell transplantation (AHSCT) as a therapeutic intervention in MS. Conclusion AHSCT is done to replace the body's immune system so that it no longer attacks the myelin or cause inflammation in a person's brain and spinal cord. Our current study is mainly focus on the quantitative and qualitative analysis of AHSC therapy against MS.